HE UNITED STATES PATENT AND TRADEMARK OFFICE

Edwin Madison et.al.

Serial No.:10/099,700

Filed:

JUN 1 7 2002

March 13, 2002

For: NUCLEIC ACID MOLECULES ENCODING A TRANSMEMBRANE SERINE PROTEASE 7, THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON

Confirmation No.: 4309

Art Unit:

1645

Examiner:

Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents

U.S. Patent and Trademark office

P.O. Box 2327

Arlington, VA 22202, on this date.

06/12/02

Date

TRANSMITTAL LETTER

RECEIVED

Commissioner for Patents U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

JUL 1 1 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith is a Preliminary Amendment for filing in connection with the above-identified application.

The Commissioner is hereby authorized to charge any fee, including any submitted herewith if X the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213.

Respectfully submitted, HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman Registration No. 33,779

Attorney Docket No.: 24745-1613 Address all correspondence to: Stephanie L. Seidman, Esq.

HELLER, EHRMAN, WHITE & McAULIFFE LLP 4350 La Jolla Village Drive, 7th Floor

San Diego, California 92122-1246

Telephone: (858) 450-8400 Facsimile: (858) 587-5360 EMAIL: sseidman@hewm.com RECEIVED

JUN 2 1 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Edwin Madison et.al.

Serial No.: 10/099,700

Filed: March 13, 2002

NUCLEIC ACID MOLECULES For: ENCODING A TRANSMEMBRANE SERINE PROTEASE 7, THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON

Confirmation No.: 4309

Art Unit: 1645

Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents

U.S. Patent and Trademark office

P.O. Box 2327

Arlington, VA 22202, on this date.

06/12/02

Date

RECEIVED

JUL 1 1 2002

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Commissioner for Patents U.S. Patent and Trademark office P.O. Box 2327

Arlington, D.C. 22202

RECEIVED

JUN 2 1 2002

TECH CENTER 1600/2900

Dear Sir:

Preliminary to examination of the above-captioned patent application, please amend the application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows (a marked-up copy of the amended specification is attached to this Amendment):

Please replace the paragraph on page 1, lines 17-29, with the following paragraph:

Cancer, which is a leading cause of death in the United States, is characterized by an increase in the number of abnormal neoplastic cells, which proliferate to form a tumor mass, the invasion of adjacent tissues by these neoplastic tumor cells, and the generation of malignant cells that metastasize via the blood or lymphatic system to regional lymph nodes and to distant sites. Among the hallmarks of cancer is a breakdown in the communication among tumor cells and their environment. Normal cells do not divide in the absence of stimulatory signals and cease dividing in the presence of inhibitory signals. Growth-stimulatory and growth-inhibitory signals, are routinely exchanged between cells within a tissue. In a cancerous, or neoplastic state, a cell